Pharming Group Forecast, price target & analysts
Pharming Group Target price 2026 - Analyst rating & recommendation
Pharming Group Classifications & Recommendation
Pharming Group Price Target
| Target Price | €2.14 |
| Price | €0.87 |
| Potential |
145.02%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Pharming Group 2027 .
The average Pharming Group target price is €2.14.
This is
145.02%
register free of charge
€2.57
194.27%
register free of charge
€1.82
107.96%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Pharming Group to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group stock has an average upside potential 2027 of
145.02%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 336.07 | 362.96 |
| 26.56% | 8.53% | |
| EBITDA Margin | 11.56% | 7.52% |
| 361.60% | 34.95% | |
| Net Margin | 0.76% | 6.70% |
| 119.04% | 785.64% |
7 Analysts have issued a sales forecast Pharming Group 2026 . The average Pharming Group sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Pharming Group EBITDA forecast 2026. The average Pharming Group EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Pharming Group Analysts have issued a net profit forecast 2026. The average Pharming Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.00 | 0.03 |
| 100.00% | ||
| P/E | 25.34 | |
| EV/Sales | 1.62 |
7 Analysts have issued a Pharming Group forecast for earnings per share. The average Pharming Group EPS is
This results in the following potential growth metrics and future valuations:
Current Pharming Group Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jul 12 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | May 08 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jul 12 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
May 08 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
May 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
